Table 2. Completeness of economic information provided in applications to the WHO Expert Committee on the Selection and Use of Essential Medicines, 2002–2013.
| Application status | No. of applications (%)a |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Price (n = 134) |
Economic evaluation (n = 134) |
|||||||||
| Complete | Incomplete | Not available | Missing | Complete | Incomplete | Not available | Not applicable | Missing | ||
| Applied | 28 (20.9) | 79 (59.0) | 7 (5.2) | 20 (14.9) | 25 (18.7) | 8 (6.0) | 28 (20.9) | 24 (17.9) | 49 (36.6) | |
| Added to list | 18 (64.3) | 43 (54.4) | 4 (57.1) | 7 (35.0) | 13 (52.0) | 5 (62.5) | 14 (50.0) | 12 (50.0) | 28 (57.1) | |
WHO: World Health Organization.
a If applicant explicitly noted that price and/or economic evaluation data did not exist for the medicine, these were classified as not available. To be classified as missing, the applicant did not provide any price or economic evaluation information. Applications classified as not applicable were those in which the economic evaluation sections did not include outcomes-based measures (i.e. neither cost–effectiveness, cost–benefit nor cost–utility analysis).